Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | EIF4A2 |
| Gene Name: | EIF4A2 |
| Protein Full Name: | Eukaryotic initiation factor 4A-II |
| Alias: | ATP-dependent RNA helicase eIF4A-2; BM-010; DDX2B; EC 3.6.1.-; EIF4A; EIF4A-II; EIF-4A-II; EIF4F; Eukaryotic translation initiation factor 4A, 2; Eukaryotic translation initiation factor 4A, isoform 2; IF4A2 |
| Mass (Da): | 46402 |
| Number AA: | 407 |
| UniProt ID: | Q14240 |
| Locus ID: | 1974 |
| COSMIC ID: | EIF4A2 |
| Gene location on chromosome: | 3q28 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19868 |
| Percent of cancer specimens with mutations: | 0.41 |
| Deregulated in translocations: | BCL6 |
| Normal role description: | EIF4A2 is part of an ATP-dependent RNA helicase complex involved in protein synthesis. It's implicated in recognition of mRNA cap, binding of mRNA to ribosome and unwinding RNA secondary structure and scanning for initiator codon. Increased expression may relate to oncogenesis to mediate the need for translation of new proteins. It may play a role in stimulating MYC activation under hypoxic conditions to stimulate cell proliferation and may promote oncogenesis. |